



Draft Online Statement

For immediate release

Amethyst Radiotherapy, leading operator of specialised oncology treatment services, statement on ABHI Clinical engagement program

Amethyst Radiotherapy, London, 19th January 2024 –

Amethyst, the largest provider of Radiotherapy services in Europe treating over 29,000 patients a year is thrilled to announce the hosting of an exceptional Clinical Engagement Program during the upcoming Arab Health event. This comprehensive program will showcase the latest advancements in the delivery of Intracranial Stereotactic Radiosurgery, with a special focus on optimizing Stereotactic Radiosurgical treatment of Neuro-vascular disease through the innovative BrainLabs Elements Treatment System.

Key highlights of Amethyst's Clinical engagement program:

1. Intracranial Stereotactic Radiosurgery Developments: Miss Murphy, Consultant Neurosurgeon at The National Hospital for Neurology and Neurosurgery, Queen Square London
 - Exploration of cutting-edge techniques in delivering Intracranial Stereotactic Radiosurgery.
 - Showcasing new advancements in optimizing Stereotactic Radiosurgical treatment of Neuro-Vascular disease using the BrainLabs Elements Treatment System
 - Miss Murphy will demonstrate the efficacy of its Elements "Angiography Contouring and "Smart Brush" modules
 - Insights into how these modules optimize diagnostic angiograms for treatment planning, enhancing the patient pathway and experience during radio-surgical

- planning and treatment.
- Led by Miss Mary Murphy, the session promises to provide valuable perspectives.
2. Post-Covid Evolution in intracranial Stereotactic Radiosurgery: Mr Ramez Ibrahim, Consultant Neurosurgeon at The Thornbury Radiosurgery Centre, Sheffield, UK
- Mr. Ramez Ibrahim, Consultant Neurosurgeon at the Royal Hallamshire Hospital, Sheffield, renowned for treating almost +1300 patients annually, will lead a discussion on how the pathology and treatment of Metastatic disease has evolved post-COVID.
3. **Discussion on Cancer Genomics: Professor Karol Sikora, former Director of the World Health Organization's Cancer Program, will chair an informal discussion on the emerging specialty of Cancer Genomics.**
- Insights into exciting new developments in genetic analysis and molecular profiling influencing new therapeutic interventions and first-line treatment for various tumors.

"We are excited to bring together experts, innovators, and thought leaders to explore and discuss the forefront of medical technology. Our Clinical Engagement Program is a testament to our commitment to advancing healthcare and improving patient outcomes," said Stephan Doroszkowski, MD at Amethyst UK.

For media inquiries, please
contact: [contactme@amethyst-
radiotherapy.co.uk](mailto:contactme@amethyst-radiotherapy.co.uk)

<< ENDS >>

About Amethyst Radiotherapy

Founded in 2010, Amethyst Radiotherapy operates some of the highest volume Linear Accelerators (Linacs) in Europe, with 220 patients a day treated in its high-volume centers; equivalent to +70 patients per Linac per day; bringing treatment times to eight minutes per treatment fraction. This is double the typical Linac utilization.

Amethyst delivers next generation (non-surgical) oncology treatment across the international Cancer Care market in Austria, France, Italy, Poland, Romania and the UK, operating 15 specialist centres, comprising 25 Linear Accelerators (Linacs) and two Gamma Knife Radiosurgery centers.